Skip to Content

Wednesday, September 26th, 2018
Home / Posts Tagged "Eli Lilly and Company"

Tag Archives: Eli Lilly and Company

Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Meeting

INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) meeting. As previously disclosed, solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a study of solanezumab initiated in people with mild dementia […]

Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial

INDIANAPOLIS, Nov. 23, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer’s disease (AD). Patients treated with solanezumab did not experience a statistically significant slowing in […]

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one year INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, […]

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)

Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate – the current standard of care – and adalimumab (Humira®)* INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase […]

Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Arthritis to be Presented at Annual European Congress of Rheumatology (EULAR 2016)

Lilly immunology portfolio to be featured in 16 presentations INDIANAPOLIS, June 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib’s phase 3 global studies will be presented, along with other phase 2b and preclinical studies, at […]

New Data Show Lilly’s Once-Weekly Trulicity® (dulaglutide) Solution for Injection is Effective as Add-on Treatment to Sulfonylurea

Trulicity 1.5 mg Demonstrates Superior Efficacy in AWARD-8 Trial INDIANAPOLIS, Dec. 1, 2015 /PRNewswire/ — New data from a completed Phase 3 trial show Trulicity® (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering HbA1c from baseline after 24 weeks of treatment.1 Trulicity is Eli Lilly and […]

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis

— Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab — Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab — Detailed results from pivotal phase 3 study RA-BEAM presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting INDIANAPOLIS, […]

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

– Compared to methotrexate, baricitinib as monotherapy or in combination with methotrexate demonstrated improvements in all ACR components as early as week 1 and maintained through 52 weeks – Both baricitinib regimens were superior to methotrexate monotherapy in inducing clinical remission, using measures such as SDAI, at weeks 24 and 52 – Baricitinib plus methotrexate […]